Edwards divests hemofiltration products
This article was originally published in The Gray Sheet
Executive Summary
Baxter will expand its renal business through the acquisition of Edwards Lifesciences' hemofiltration products for continuous renal replacement therapy, paying $56 million in cash, plus up to $9 million in milestones. Baxter currently is the exclusive distributor of the Edwards products in the U.S., Latin America and China, and the product line generated $50 million in sales in 2008, primarily in Europe. The divestiture will allow heart valve and hemodynamic monitoring firm Edwards to "focus on its global strategic priorities," the firm says